Drug intelligence / Profile preview

Debio 0532

Development stage: Preclinical
Lead developer: Debiopharm
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous (inferred From Adc Class; Not Explicitly Stated)

Overview

Debio 0532 is a novel antibody-drug conjugate (ADC) developed by Debiopharm for the treatment of solid tumors in oncology. It specifically targets tumor-specific antigens, with a focus on the HER3 (Receptor tyrosine-protein kinase erbB-3) receptor, which is implicated in cancer cell growth and survival. The ADC leverages Debiopharm’s proprietary Multilink™ linker technology to enable high drug-to-antibody ratios and enhanced stability. This design aims to deliver cytotoxic payloads directly to HER3-expressing tumor cells while minimizing off-target effects, addressing cancers with high unmet medical needs[1][4][5][6][10].

Targets

ERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on Debio 0532.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Debio 0532.

Explore the full profile